Effect of Overexpression of SET and MYND Domain Containing Protein 3 Gene (SMYD3) in Bovine (Bos taurus) Embryonic Fibroblast Cells (bEFs) on the Cells Proliferation and the Efficiency for Induced Pluripotent Stem Cells (iPSCs)
Abstract：SET and MYND domain-containing protein 3 (SMYD3) is a histone H3 Lysine 4 trimethyltransferase, which overexpresses in many cancers and can promote cells proliferation, migration and invasion. In order to study the function of SMYD3 in bovine embryonic fibroblast cells (bEFs), SMYD3 CDS was obtained from bovine (Bos taurus) and inserted into the vector pIRES2-Zsgreen1 to construct overexpression vector pSMYD3-IRES2-Zsgreen1. pSMYD3-IRES2-Zsgreen1 was transfected into bEFs and qRT-PCR and Western blot were used to verify its expression. Also, the cell growth was recorded by detecting the absorbancy of 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di- phenytetrazoliumromide (MTT) every 24 h for 7 d. At last, the transgenic bEFs were infected with lentiviral vectors expressing the mouse (Mus musculus) octamer-binding transcription factor 4 (Oct4), SRY (sex determining region Y)-box 2 (Sox2), avian myelocytomatosis viral oncogene homolog (c-Myc) and Kruppel-like factor 4 (Klf4) transcription factors, respectively, to obtain the bovine induced pluripotent stem cells (iPSCs). The enzyme digestion results showed that the vector pSMYD3-IRES2-Zsgreen1 was correctly constructed. The qRT-PCR and Western blot results indicated that SMYD3 overexpressed in pSMYD3-IRES2-Zsgreen1 transfected bEFs, which cells growth improved comparing with the control vector transgenic cells. After induction by the 4 transcription factors, the SMYD3 transgenic cells formed more stem cell-like clones, which displayed OCT4, NANOG homeobox (NANOG) and SOX2 immunofluorescence staining positively. These results established and firstly reported that SMYD3 could promote bEFs growth and induction efficiency for iPSCs, which provides basic data for the strategies of preparing bovine iPSCs and improves understanding of the molecular basis of iPSCs.
[1]Abu-Farha, M., Lambert, J.-P., Al-Madhoun, A.S., et al. 2008. The Tale of Two Domains Proteomics and Genomics Analysis of SMYD2, A New Histone Methyltransferase[J]. Molecular & Cellular Proteomics 7, 560-572.[2]Bao, L., He, L., Chen, J., et al. 2011. Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors[J]. Cell research 21, 600-608.[3]Brambrink, T., Foreman, R., Welstead, G.G., et al. 2008. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells[J]. Cell stem cell 2, 151-159.[4]Brown, M.A., Sims, R.J., Gottlieb, P.D., et al. 2006. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex[J]. Molecular cancer 5, 26.[5]Chai, S., Smith, R., Fitter, J., et al. 2014. Increased progesterone receptor A expression in labouring human myometrium is associated with decreased promoter occupancy by the histone demethylase JARID1A[J]. Molecular human reproduction 20, 442-453.[6]Chen, L.-B., Xu, J.-Y., Yang, Z., et al. 2007. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration[J]. World journal of gastroenterology: WJG 13, 5718-5724.[7]Cock-Rada, A.M., Medjkane, S., Janski, N., et al. 2012. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9[J]. Cancer research 72, 810-820.[8]Fujii, T., Tsunesumi, S.-i., Yamaguchi, K., et al. 2011. Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish[J]. PloS one 6, e23491.[9]Hamamoto, R., Furukawa, Y., Morita, M., et al. 2004. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells[J]. Nature cell biology 6, 731-740.[10]Hamamoto, R., Silva, F.P., Tsuge, M., et al. 2006. Enhanced SMYD3 expression is essential for the growth of breast cancer cells[J]. Cancer science 97, 113-118.[11]Han, X., Han, J., Ding, F., et al. 2011. Generation of induced pluripotent stem cells from bovine embryonic fibroblast cells[J]. Cell research 21, 1509-1512.[12]Honda, A., Hirose, M., Hatori, M., et al. 2010. Generation of induced pluripotent stem cells in rabbits potential experimental models for human regenerative medicine[J]. Journal of Biological Chemistry 285, 31362-31369.[13]Kwon, T., Chang, J.H., Kwak, E., et al. 2003. Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9—AdoMet[J]. The EMBO journal 22, 292-303.[14]Li, J., Moazed, D., and Gygi, S.P. 2002. Association of the histone methyltransferase Set2 with RNA polymerase II plays a role in transcription elongation[J]. Journal of Biological Chemistry 277, 49383-49388.[15]Liao, J., Cui, C., Chen, S., et al. 2009. Generation of induced pluripotent stem cell lines from adult rat cells[J]. Cell stem cell 4, 11-15.[16]Liu, C., Fang, X., Ge, Z., et al. 2007a. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3[J]. Cancer research 67, 2626-2631.[17]Liu, H., Zhu, F., Yong, J., et al. 2008. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts[J]. Cell stem cell 3, 587-590.[18]Liu, Y., Chen, W., Gaudet, J., et al. 2007b. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity[J]. Cancer cell 11, 483-497.[19]Lluis, F., Pedone, E., Pepe, S., et al. 2008. Periodic activation of Wnt/β-catenin signaling enhances somatic cell reprogramming mediated by cell fusion[J]. Cell stem cell 3, 493-507.[20]Luo, X.G., Zou, J.N., Wang, S.Z., et al. 2010. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA‐MB‐231 human breast cancer cells[J]. IUBMB life 62, 194-199.[21]Marson, A., Foreman, R., Chevalier, B., et al. 2008. Wnt signaling promotes reprogramming of somatic cells to pluripotency[J]. Cell stem cell 3, 132.[22]Mazur, P.K., Reynoird, N., Khatri, P., et al. 2014. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer[J]. Nature 510, 283-287.[23]Nagy, K., Sung, H.-K., Zhang, P., et al. 2011. Induced pluripotent stem cell lines derived from equine fibroblasts[J]. Stem Cell Reviews and Reports 7, 693-702.[24]Ng, H.H., Robert, F., Young, R.A., et al. 2003. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity[J]. Molecular cell 11, 709-719.[25]O'Carroll, D., Scherthan, H., Peters, A.H., et al. 2000. Isolation and Characterization of Suv39h2, a Second Histone H3 Methyltransferase Gene That Displays Testis-Specific Expression[J]. Molecular and cellular biology 20, 9423-9433.[26]Proserpio, V., Fittipaldi, R., Ryall, J.G., et al. 2013. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy[J]. Genes & development 27, 1299-1312.[27]Rea, S., Eisenhaber, F., O'Carroll, D., et al. 2000. Regulation of chromatin structure by site-specific histone H3 methyltransferases[J]. Nature 406, 593-599.[28]Ren, T.-n., Wang, J.-s., He, Y.-m., et al. 2011. Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells[J]. Medical Oncology 28, 91-98.[29]Sims, R.J., Nishioka, K., and Reinberg, D. 2003. Histone lysine methylation: a signature for chromatin function[J]. TRENDS in Genetics 19, 629-639.[30]Sims, R.J., and Reinberg, D. 2004. From chromatin to cancer: a new histone lysine methyltransferase enters the mix[J]. Nature cell biology 6, 685-687.[31]Tachibana, M., Sugimoto, K., Fukushima, T., et al. 2001. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3[J]. Journal of Biological Chemistry 276, 25309-25317.[32]Tan, X., Rotllant, J., Li, H., et al. 2006. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos[J]. Proceedings of the National Academy of Sciences of the United States of America 103, 2713-2718.[33]Wang, S., Luo, X., Shen, J., et al. 2008. Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro[J]. BMB Rep 41, 294-299.[34]Wernig, M., Lengner, C.J., Hanna, J., et al. 2008. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types[J]. Nature biotechnology 26, 916-924.[35]Zou, J.-N., Wang, S.-Z., Yang, J.-S., et al. 2009. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF[J]. Cancer letters 280, 78-85.
